ANXA5 and chronic myelogenous leukemia, BCR-ABL1 positive: Next, we tested patient samples, with three healthy donor, three myeloid BP-CML (as used previously), and three lymphoid BP-CML samples treated with 5 μM nilotinib and/or 1 μM BH3 mimetics and Annexin V/DAPI staining was measured after 72 h (Fig. 8A).